Lung cancer drug combo shows promise in early trial
NCT ID NCT00596648
First seen Jan 20, 2026 · Last updated May 22, 2026 · Updated 17 times
Summary
This study tested a drug called cabozantinib, either alone or with another drug (erlotinib), in people with advanced non-small cell lung cancer whose cancer had stopped responding to erlotinib. The goal was to find safe doses and see if the combination could shrink tumors. 92 adults took part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Case Western Reserve University
Cleveland, Ohio, 44106, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Georgetown University/Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, 20007, United States
-
Katmai Oncology Group
Anchorage, Alaska, 99508, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Park Nicollet Institute
Saint Louis Park, Minnesota, 55416, United States
-
Stanford University Medical Center
Palo Alto, California, 94305, United States
-
Summit Medical Group
Berkeley Heights, New Jersey, 07922, United States
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
University of California, Davis
Sacramento, California, 95817, United States
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of Washington/ Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
-
Yale University School of Medicine
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.